Earnings To Watch: Pediatrix Medical Group (MD) Reports Q2 Results Tomorrow

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Pediatrix Medical Group beat analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $458.4 million, down 7.4% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ same-store sales estimates and a solid beat of analysts’ EPS estimates.

Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Pediatrix Medical Group’s revenue to decline 7.9% year on year to $464.4 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 18.5%, beating analysts’ expectations by 0.7%, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. The Ensign Group traded up 8.7% following the results while CVS Health’s stock price was unchanged.

Read our full analysis of The Ensign Group’s results here and CVS Health’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Pediatrix Medical Group is down 10.9% during the same time and is heading into earnings with an average analyst price target of $17.14 (compared to the current share price of $11.98).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.